Unraveling the biology of a fungal meningitis pathogen using chemical genetics

Cell

Volumn 159, Issue 5, 2014, Pages 1168-1187

  Brown, Jessica C S ^a   Nelson, Justin ^b   Vandersluis, Benjamin ^b   Deshpande, Raamesh ^b   Butts, Arielle ^c   Kagan, Sarah ^d   Polacheck, Itzhack ^d   Krysan, Damian J ^c,e   Myers, Chad L ^b   Madhani, Hiten D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Minnesota   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PROTEIN TYROSINE PHOSPHATASE; TOREMIFENE; VIRULENCE FACTOR;

ALGORITHM; ARTICLE; CELL CYCLE; CELL SURFACE; CHEMICAL GENETICS; CRYPTOCOCCUS NEOFORMANS; FUNGAL GENETICS; FUNGAL MENINGITIS; FUNGAL VIRULENCE; FUNGUS GROWTH; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE ONTOLOGY; GENETIC ANALYSIS; MORTALITY; NONHUMAN; PATHOGENICITY; PHENOTYPE; PREDICTION; SACCHAROMYCES CEREVISIAE; AIDS RELATED COMPLEX; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENE INACTIVATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALGORITHMS; ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DRUG DISCOVERY; GENE KNOCKOUT TECHNIQUES; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE; VIRULENCE FACTORS;

EID: 84911498408     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2014.10.044     Document Type: Article

References (65)

1. S.F. Altschul, T.L. Madden, A.A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 25 1997 3389 3402
2. J.B. Anderson Evolution of antifungal-drug resistance: mechanisms and pathogen fitness Nat. Rev. Microbiol. 3 2005 547 556
3. D. Armstrong-James, G. Meintjes, and G.D. Brown A neglected epidemic: fungal infections in HIV/AIDS Trends Microbiol. 22 2014 120 127
4. A. Baryshnikova, M. Costanzo, Y. Kim, H. Ding, J. Koh, K. Toufighi, J.-Y. Youn, J. Ou, B.-J. San Luis, and S. Bandyopadhyay Quantitative analysis of fitness and genetic interactions in yeast on a genome scale Nat. Methods 7 2010 1017 1024
5. D. Broek, R. Bartlett, K. Crawford, and P. Nurse Involvement of p34cdc2 in establishing the dependency of S phase on mitosis Nature 349 1991 388 393
6. A. Butts, and D.J. Krysan Antifungal drug discovery: something old and something new PLoS Pathog. 8 2012 e1002870
7. A. Butts, L. DiDone, K. Koselny, B.K. Baxter, Y. Chabrier-Rosello, M. Wellington, and D.J. Krysan A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis Eukaryot. Cell 12 2013 278 287
8. A. Butts, K. Koselny, Y. Chabrier-Roselló, C.P. Semighini, J.C.S. Brown, X. Wang, S. Annadurai, L. DiDone, J. Tabroff, and W.E. Childers Jr. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo MBio 5 2014 e00765-e13
9. L. Cantas, S.Q.A. Shah, L.M. Cavaco, C.M. Manaia, F. Walsh, M. Popowska, H. Garelick, H. Bürgmann, and H. Sørum A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota Front Microbiol 4 2013 96
10. Y.C. Chang, and K.J. Kwon-Chung Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans Infect. Immun. 66 1998 2230 2236
11. C.D. Chun, J.C.S. Brown, and H.D. Madhani A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans Cell Host Microbe 9 2011 243 251
12. M. Cokol, H.N. Chua, M. Tasan, B. Mutlu, Z.B. Weinstein, Y. Suzuki, M.E. Nergiz, M. Costanzo, A. Baryshnikova, and G. Giaever Systematic exploration of synergistic drug pairs Mol. Syst. Biol. 7 2011 544
13. S.R. Collins, K.M. Miller, N.L. Maas, A. Roguev, J. Fillingham, C.S. Chu, M. Schuldiner, M. Gebbia, J. Recht, and M. Shales Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map Nature 446 2007 806 810
14. M. Costanzo, A. Baryshnikova, J. Bellay, Y. Kim, E.D. Spear, C.S. Sevier, H. Ding, J.L.Y. Koh, K. Toufighi, and S. Mostafavi The genetic landscape of a cell Science 327 2010 425 431
15. M. Del Poeta Role of phagocytosis in the virulence of Cryptococcus neoformans Eukaryot. Cell 3 2004 1067 1075
16. J.C. Dittmar, R.J. Reid, and R. Rothstein ScreenMill: a freely available software suite for growth measurement, analysis and visualization of high-throughput screen data BMC Bioinformatics 11 2010 353 363
17. T.L. Doering How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans Annu. Rev. Microbiol. 63 2009 223 247
18. M. Feldman, A. Al-Quntar, I. Polacheck, M. Friedman, and D. Steinberg Therapeutic potential of thiazolidinedione-8 as an antibiofilm agent against Candida albicans PLoS ONE 9 2014 e93225
19. L. Fernández, and R.E.W. Hancock Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance Clin. Microbiol. Rev. 25 2012 661 681
20. A.R. Florio, S. Ferrari, E. De Carolis, R. Torelli, G. Fadda, M. Sanguinetti, D. Sanglard, and B. Posteraro Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A BMC Microbiol. 11 2011 97
21. L.K. Francis, Y. Alsayed, X. Leleu, X. Jia, U.K. Singha, J. Anderson, M. Timm, H. Ngo, G. Lu, and A. Huston Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma Clin. Cancer Res. 12 2006 6826 6835
22. J.A. Geyer, S.T. Prigge, and N.C. Waters Targeting malaria with specific CDK inhibitors Biochim. Biophys. Acta 1754 2005 160 170
23. M.A. Ghannoum, and L.B. Rice Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance Clin. Microbiol. Rev. 12 1999 501 517
24. B.C. Haynes, M.L. Skowyra, S.J. Spencer, S.R. Gish, M. Williams, E.P. Held, M.R. Brent, and T.L. Doering Toward an integrated model of capsule regulation in Cryptococcus neoformans PLoS Pathog. 7 2011 e1002411
25. J. Heitman, T.R. Kozel, K.J. Kwon-Chung, J.R. Perfect, and A. Casadevall Cryptococcus: from human pathogen to model yeast 2011 ASM Press Washington, D.C.
26. H.D. Hill, G.K. Summer, and M.D. Waters An automated fluorometric assay for alkaline phosphatase using 3-O-methylfluorescein phosphate Anal. Biochem. 24 1968 9 17
27. M.E. Hillenmeyer, E. Fung, J. Wildenhain, S.E. Pierce, S. Hoon, W. Lee, M. Proctor, R.P. St Onge, M. Tyers, and D. Koller The chemical genomic portrait of yeast: uncovering a phenotype for all genes Science 320 2008 362 365
28. M.H. Hsieh, C.M. Yu, V.L. Yu, and J.W. Chow Synergy assessed by checkerboard. A critical analysis Diagn. Microbiol. Infect. Dis. 16 1993 343 349
29. G. Janbon, K.L. Ormerod, D. Paulet, E.J. Byrnes III, V. Yadav, G. Chatterjee, N. Mullapudi, C.-C. Hon, R.B. Billmyre, and F. Brunel Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complex RNA expression and microevolution leading to virulence attenuation PLoS Genet. 10 2014 e1004261
30. G. Jansen, A.Y. Lee, E. Epp, A. Fredette, J. Surprenant, D. Harcus, M. Scott, E. Tan, T. Nishimura, and M. Whiteway Chemogenomic profiling predicts antifungal synergies Mol. Syst. Biol. 5 2009 338
31. B. Jiang, D. Xu, J. Allocco, C. Parish, J. Davison, K. Veillette, S. Sillaots, W. Hu, R. Rodriguez-Suarez, and S. Trosok PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products Chem. Biol. 15 2008 363 374
32. S. Kagan, A. Jabbour, E. Sionov, A.A. Alquntar, D. Steinberg, M. Srebnik, R. Nir-Paz, A. Weiss, and I. Polacheck Anti-Candida albicans biofilm effect of novel heterocyclic compounds J. Antimicrob. Chemother. 69 2014 416 427
33. L. Kalan, and G.D. Wright Antibiotic adjuvants: multicomponent anti-infective strategies Expert Rev. Mol. Med. 13 2011 e5
34. M.K. Kathiravan, A.B. Salake, A.S. Chothe, P.B. Dudhe, R.P. Watode, M.S. Mukta, and S. Gadhwe The biology and chemistry of antifungal agents: a review Bioorg. Med. Chem. 20 2012 5678 5698
35. T.R. Kozel, and C.A. Hermerath Binding of cryptococcal polysaccharide to Cryptococcus neoformans Infect. Immun. 43 1984 879 886
36. T.R. Kozel, S.M. Levitz, F. Dromer, M.A. Gates, P. Thorkildson, and G. Janbon Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains Infect. Immun. 71 2003 2868 2875
37. R. Kumar, A. Musiyenko, and S. Barik Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin Mol. Biochem. Parasitol. 141 2005 29 37
38. P. Kumar, M. Yang, B.C. Haynes, M.L. Skowyra, and T.L. Doering Emerging themes in cryptococcal capsule synthesis Curr. Opin. Struct. Biol. 21 2011 597 602
39. P. Kumar, C. Heiss, F.H. Santiago-Tirado, I. Black, P. Azadi, and T.L. Doering Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly Eukaryot. Cell 13 2014 560 571
40. D. Kuo, K. Tan, G. Zinman, T. Ravasi, Z. Bar-Joseph, and T. Ideker Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering Genome Biol. 11 2010 R77
41. J. Lehár, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, E.R. Price, R.J. Rickles, G.F. Short 3rd, J.E. Staunton, and X. Jin Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
42. C. Liu, J. Apodaca, L.E. Davis, and H. Rao Proteasome inhibition in wild-type yeast Saccharomyces cerevisiae cells Biotechniques 42 2007 158 162 160, 162
43. O.W. Liu, M.J.S. Kelly, E.D. Chow, and H.D. Madhani Parallel β-helix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans Eukaryot. Cell 6 2007 630 640
44. O.W. Liu, C.D. Chun, E.D. Chow, C. Chen, H.D. Madhani, and S.M. Noble Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans Cell 135 2008 174 188
45. A. Loyse, T. Bicanic, and J.N. Jarvis Combination antifungal therapy for cryptococcal meningitis N. Engl. J. Med. 368 2013 2522 2523
46. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. Aggarwal, and S.Y. Ahn Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
47. G.L. Mandell, J.E. Bennett, and R. Dolin Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 7th edn 2010 Churchill Livingstone Elsevier Philadelphia
48. J. Meletiadis, S. Pournaras, E. Roilides, and T.J. Walsh Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus Antimicrob. Agents Chemother. 54 2010 602 609
49. D.O. Morgan The Cell Cycle: Principles of Control 2007 New Science Press London, UK
50. R.J. Nichols, S. Sen, Y.J. Choo, P. Beltrao, M. Zietek, R. Chaba, S. Lee, K.M. Kazmierczak, K.J. Lee, and A. Wong Phenotypic landscape of a bacterial cell Cell 144 2011 143 156
51. T.R. O'Meara, and J.A. Alspaugh The Cryptococcus neoformans capsule: a sword and a shield Clin. Microbiol. Rev. 25 2012 387 408
52. T.R. O'Meara, D. Norton, M.S. Price, C. Hay, M.F. Clements, C.B. Nichols, and J.A. Alspaugh Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule PLoS Pathog. 6 2010 e1000776
53. B.J. Park, K.A. Wannemuehler, B.J. Marston, N. Govender, P.G. Pappas, and T.M. Chiller Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS AIDS 23 2009 525 530
54. A.B. Parsons, R.L. Brost, H. Ding, Z. Li, C. Zhang, B. Sheikh, G.W. Brown, P.M. Kane, T.R. Hughes, and C. Boone Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways Nat. Biotechnol. 22 2004 62 69
55. A.B. Parsons, A. Lopez, I.E. Givoni, D.E. Williams, C.A. Gray, J. Porter, G. Chua, R. Sopko, R.L. Brost, and C.-H. Ho Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast Cell 126 2006 611 625
56. L. Pu, A.A. Amoscato, M.E. Bier, and J.S. Lazo Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione J. Biol. Chem. 277 2002 46877 46885
57. A.J. Reese, and T.L. Doering Cell wall α-1,3-glucan is required to anchor the Cryptococcus neoformans capsule Mol. Microbiol. 50 2003 1401 1409
58. T. Roemer, D. Xu, S.B. Singh, C.A. Parish, G. Harris, H. Wang, J.E. Davies, and G.F. Bills Confronting the challenges of natural product-based antifungal discovery Chem. Biol. 18 2011 148 164
59. M. Taipale, D.F. Jarosz, and S. Lindquist HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 11 2010 515 528
60. A. Vecchiarelli, E. Pericolini, E. Gabrielli, S. Kenno, S. Perito, E. Cenci, and C. Monari Elucidating the immunological function of the Cryptococcus neoformans capsule Future Microbiol. 8 2013 1107 1116
61. W.L. Whelan, and K.J. Kwon-Chung Genetic complementation in Cryptococcus neoformans J. Bacteriol. 166 1986 924 929
62. WHO Rapid Advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children W.H.O. Library 2011 WHO Press Geneva, Switzerland
63. D. Xu, B. Jiang, T. Ketela, S. Lemieux, K. Veillette, N. Martel, J. Davison, S. Sillaots, S. Trosok, and C. Bachewich Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans PLoS Pathog. 3 2007 e92
64. D. Xu, S. Sillaots, J. Davison, W. Hu, B. Jiang, S. Kauffman, N. Martel, P. Ocampo, C. Oh, and S. Trosok Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans J. Biol. Chem. 284 2009 19754 19764
65. B. Zhai, C. Wu, L. Wang, M.S. Sachs, and X. Lin The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections Antimicrob. Agents Chemother. 56 2012 3758 3766